RELIANCE BIOSCIENCES delivers molecular diagnostics
via exosomes for diagnostic and assessment of
neurodegenerative diseases and unmet clinical needs.
Exosomes are nanoparticles secreted from disease-specific cells and provide personalized and actionable disease insights. Our proprietary immunoassay technology enables high sensitivity exosomal protein detection using blood.
OUR CURRENT FOCUS

OUR CURRENT FOCUS
UNMET NEEDS
People worldwide living with Alzheimer’s in 2021
our PIPELINE


PARTNERSHIP
TECHNICAL MILESTONES
1. Seed grant
Seed grant of USD 1.1 million successfully executed.
2. Licensing
Exclusively licensed technology from the National Taiwan University.
3. Prototypes
RExo-system completed: (a) RExo-analyzer: multiplex sample preparation & analysis and (b) RExo-assay: multiplex fluidic assay
4. Executed Agreement
Fully executed agreement with an Australian Alzheimer organization with 8,500 contact-patient-year samples available for fast-track study on AD, with PET scan data as control.
5. MTA executed
MTA fully executed with Harvard Med School/MGH with 500 samples for early assessment of lung cancer.
6. NDA executed
Multiple NDAs fully executed with pharmas and organizations towards clinical development.